MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329215 | Name: Bromperidol
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bromperidol, also known as Impromen and R-11333, is used as a means of long-term maintenance treatment of schizophrenia. Bromperidol is a close structural analogue of haloperidol. Bromperidol is a butyrophenone derivative. It is a potent and long-acting neuroleptic.

Chemical Structure

Bromperidol
Bromperidol
CAS#10457-90-6

Theoretical Analysis

MedKoo Cat#: 329215

Name: Bromperidol

CAS#: 10457-90-6

Chemical Formula: C21H23BrFNO2

Exact Mass: 419.0896

Molecular Weight: 420.32

Elemental Analysis: C, 60.01; H, 5.52; Br, 19.01; F, 4.52; N, 3.33; O, 7.61

Price and Availability

Size Price Availability Quantity
100mg USD 950.00 2 Weeks
200mg USD 1,650.00 2 Weeks
500mg USD 2,650.00 2 Weeks
1g USD 3,650.00 2 Weeks
2g USD 6,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Bromperidol; R-11333; R 11333; R11333; Impromen; Bromidol, Bromodol;
IUPAC/Chemical Name
4-(4-(4-bromophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one
InChi Key
RKLNONIVDFXQRX-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
SMILES Code
O=C(C1=CC=C(F)C=C1)CCCN2CCC(O)(C3=CC=C(Br)C=C3)CC2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 420.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Purgato M, Adams CE. Bromperidol decanoate (depot) for schizophrenia. Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD001719. doi: 10.1002/14651858.CD001719.pub4. PMID: 23152208; PMCID: PMC7061326. 2: Purgato M, Adams CE. Bromperidol decanoate (depot) for schizophrenia. Cochrane Database Syst Rev. 2011 Sep 7;(9):CD001719. doi: 10.1002/14651858.CD001719.pub3. Update in: Cochrane Database Syst Rev. 2012;11:CD001719. PMID: 21901678. 3: Benfield P, Ward A, Clark BG, Jue SG. Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses. Drugs. 1988 Jun;35(6):670-84. doi: 10.2165/00003495-198835060-00004. PMID: 3048975. 4: Wong D, Adams CE, David A, Quraishi SN. Depot bromperidol decanoate for schizophrenia. Cochrane Database Syst Rev. 2004;(3):CD001719. doi: 10.1002/14651858.CD001719.pub2. Update in: Cochrane Database Syst Rev. 2011;(9):CD001719. PMID: 15266450. 5: Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol. 2014;9(3):310-7. doi: 10.2174/15748847113089990051. PMID: 23343447. 6: Quraishi S, David A, Adams CE. Depot bromperidol decanoate for schizophrenia. Cochrane Database Syst Rev. 2000;(2):CD001719. doi: 10.1002/14651858.CD001719. Update in: Cochrane Database Syst Rev. 2004;(3):CD001719. PMID: 10796447. 7: Tischio J, Hetyei N, Patrick J. Bromperidol radioimmunoassay: human plasma levels. J Pharm Sci. 1984 Apr;73(4):546-8. doi: 10.1002/jps.2600730428. PMID: 6726642. 8: Suzuki A, Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Kaneko S, Inoue Y, Shibata M, Ikeda K. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Ther Drug Monit. 1997 Jun;19(3):261-4. doi: 10.1097/00007691-199706000-00003. PMID: 9200764. 9: Sato S, Someya T, Shioiri O, Koitabashi T, Inoue Y. Involvement of CYP3A4 in the metabolism of bromperidol in vitro. Pharmacol Toxicol. 2000 Mar;86(3):145-8. doi: 10.1034/j.1600-0773.2000.d01-27.x. PMID: 10752674. 10: Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Suzuki A, Furukori H, Kaneko S, Inoue Y. Interaction between carbamazepine and bromperidol. Eur J Clin Pharmacol. 1997;52(3):219-22. doi: 10.1007/s002280050277. PMID: 9218929. 11: Ostuzzi G, Bertolini F, Del Giovane C, Tedeschi F, Bovo C, Gastaldon C, Nosé M, Ogheri F, Papola D, Purgato M, Turrini G, Correll CU, Barbui C. Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. Am J Psychiatry. 2021 May 1;178(5):424-436. doi: 10.1176/appi.ajp.2020.20071120. Epub 2021 Feb 18. PMID: 33596679. 12: Dubinsky B, McGuire JL, Niemegeers CJ, Janssen PA, Weintraub HS, McKenzie BE. Bromperidol, a new butyrophenone neuroleptic: a review. Psychopharmacology (Berl). 1982;78(1):1-7. doi: 10.1007/BF00470578. PMID: 6128755. 13: Suzuki A, Otani K, Mihara K, Yasui N, Kondo T, Tokinaga N, Furukori H, Kaneko S, Inoue Y, Hayashi K. Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite. Psychopharmacology (Berl). 1998 Feb;135(4):333-7. doi: 10.1007/s002130050519. PMID: 9539256. 14: Yasui N, Otani K, Kondo T, Suzuki A, Furukori H, Kaneko S, Inoue Y. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol. Prog Neuropsychopharmacol Biol Psychiatry. 1998 Apr;22(3):485-92. doi: 10.1016/s0278-5846(98)00019-0. PMID: 9612845. 15: Wong FA, Bateman CP, Shaw CJ, Patrick JE. Biotransformation of bromperidol in rat, dog, and man. Drug Metab Dispos. 1983 Jul-Aug;11(4):301-7. PMID: 6137334. 16: Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Kaneko S, Otani K. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):575-8. doi: 10.1016/s0278-5846(01)00310-4. PMID: 11999910. 17: Mihara K, Otani K, Yasui N, Ishida M, Kondo T, Suzuki A, Furukori H, Nagashima U, Kaneko S, Inoue Y. No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol. Ther Drug Monit. 1999 Jun;21(3):297-300. doi: 10.1097/00007691-199906000-00007. PMID: 10365640. 18: Furukori H, Kondo T, Yasui N, Otani K, Tokinaga N, Nagashima U, Kaneko S, Inoue Y. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. Psychopharmacology (Berl). 1999 Jul;145(2):189-92. doi: 10.1007/s002130051048. PMID: 10463320. 19: Suzuki A, Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Kaneko S, Inoue Y. No interaction between desipramine and bromperidol. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Oct;20(7):1265-71. doi: 10.1016/s0278-5846(96)00111-x. PMID: 8938825. 20: Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Suzuki A, Kaneko S, Inoue Y, Shibata M, Ikeda K. No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite. Ther Drug Monit. 1997 Apr;19(2):165-8. doi: 10.1097/00007691-199704000-00008. PMID: 9108644.